Abstract
Tumor antigenic peptides therapeutics is a promising field for cancer immunotherapy; advantages include convenient synthesis and modification of antigenic peptides, as well as little toxicity associated with its administration. Vaccination of the peptides derived from tumor-associated antigen (TAA) was specifically designed for T cells in the context of MHC molecules. In the past decades, tumor antigenic peptides have been examined in clinic but numbered success has been obtained because of the stability of peptide and delivery approaches, consequently leading to an inefficient antigen presentation and low response rates in cancer patients. Thus, the appropriate and efficient peptide vaccine carrier systems still continue to be a major obstacle. However, both sipuleucel-T vaccine and anti-CTLA-4 antibody have been approved by FDA for the treatment of metastatic prostate cancer and melanoma, respectively. PLGA has been recently used as the adjuvant to elicit enhanced immune responses while delivering tumor antigenic peptides. Intracellular delivery of the peptides derived from TAA into DCs would prolong antigen presentation of APC to T cells. This article aims to describe a new delivery method regarding tumor antigenic peptides and rationales of DCs-based vaccination.
Keywords: Antigen-presenting cells (APC), cancer immunotherapy, cytotoxic T lymphocytes (CTL), dendritic cells (DCs), PLGA-nanoparticle (PLGA-NPs), peptide, tumor-associated antigen (TAA).
Current Medicinal Chemistry
Title:Intracellular Delivery of Tumor Antigenic Peptides in Biodegradablepolymer Adjuvant for Enhancing Cancer Immunotherapy
Volume: 21 Issue: 21
Author(s): H. Li and W. Ma
Affiliation:
Keywords: Antigen-presenting cells (APC), cancer immunotherapy, cytotoxic T lymphocytes (CTL), dendritic cells (DCs), PLGA-nanoparticle (PLGA-NPs), peptide, tumor-associated antigen (TAA).
Abstract: Tumor antigenic peptides therapeutics is a promising field for cancer immunotherapy; advantages include convenient synthesis and modification of antigenic peptides, as well as little toxicity associated with its administration. Vaccination of the peptides derived from tumor-associated antigen (TAA) was specifically designed for T cells in the context of MHC molecules. In the past decades, tumor antigenic peptides have been examined in clinic but numbered success has been obtained because of the stability of peptide and delivery approaches, consequently leading to an inefficient antigen presentation and low response rates in cancer patients. Thus, the appropriate and efficient peptide vaccine carrier systems still continue to be a major obstacle. However, both sipuleucel-T vaccine and anti-CTLA-4 antibody have been approved by FDA for the treatment of metastatic prostate cancer and melanoma, respectively. PLGA has been recently used as the adjuvant to elicit enhanced immune responses while delivering tumor antigenic peptides. Intracellular delivery of the peptides derived from TAA into DCs would prolong antigen presentation of APC to T cells. This article aims to describe a new delivery method regarding tumor antigenic peptides and rationales of DCs-based vaccination.
Export Options
About this article
Cite this article as:
Li H. and Ma W., Intracellular Delivery of Tumor Antigenic Peptides in Biodegradablepolymer Adjuvant for Enhancing Cancer Immunotherapy, Current Medicinal Chemistry 2014; 21 (21) . https://dx.doi.org/10.2174/092986732121140521100224
DOI https://dx.doi.org/10.2174/092986732121140521100224 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Diversity of Hydroxamic Acids: Part II. Potential Therapeutic Applications
Mini-Reviews in Medicinal Chemistry Metabolism-based Drug-drug Interactions in Patients with Chronic Respiratory Diseases: A Review Focusing on Drugs Affecting the Respiratory System
Current Drug Metabolism Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Intestinal Dysbiosis, Gut Hyperpermeability and Bacterial Translocation: Missing Links Between Depression, Obesity and Type 2 Diabetes
Current Pharmaceutical Design The Bcl-2 Family as a Rational Target for the Treatment of B-Cell Chronic Lymphocytic Leukaemia
Current Medicinal Chemistry Nutritional and Therapeutic Potential of Garlic and Onion (Allium sp.)
Current Nutrition & Food Science Therapeutic and Diagnostic Applications of Nanoparticles
Current Drug Targets Synthesis and In-Vitro Antitumor Activity of Selected 7-Fluoro-6-(4-methyl-1-piperazinyl)-2-(thiosubstituted)-4(3H)-quinazolinones
Letters in Organic Chemistry Polyethyleneimine-Based Nanocarriers for Gene Delivery
Current Pharmaceutical Design Hematopoietic Stem Cells Therapies
Current Stem Cell Research & Therapy Emerging Insights in the Role of Tissue Factor in Cancer
Current Genomics Therapeutic Vaccines for Cervical Cancer: Dendritic Cell-Based Immunotherapy
Current Pharmaceutical Design Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Anti-Cancer Agents in Medicinal Chemistry Regulation of Hypoxia-inducible Factor-1α and Vascular Endothelial Growth Factor Signaling by Plant Flavonoids
Mini-Reviews in Medicinal Chemistry Naphthoquinone Derivatives Isolated from Plants: Recent Advances in Biological Activity
Mini-Reviews in Medicinal Chemistry Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Exploring Single Nucleotide Polymorphisms in ITGAV for Gastric, Pancreatic and Liver Malignancies: An Approach Towards the Discovery of Biomarker
Combinatorial Chemistry & High Throughput Screening Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued)